Stock market today: S&P 500 ekes out gain as Trump says open to deals on tariffs
Director of uniQure N.V. (NASDAQ:QURE), Balachandran Madhavan, sold 2,112 ordinary shares of the company on June 20, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The biotechnology company, currently valued at $782 million, has seen its stock surge over 213% in the past year, according to InvestingPro data. The shares were sold at a weighted average price of $14.45, resulting in a total transaction value of $30,518. The prices for the shares sold ranged from $14.40 to $14.50.
Following the transaction, Madhavan directly owns 37,697 ordinary shares of uniQure N.V.
The sale was executed to cover estimated withholding taxes upon the vesting of restricted share units, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The filing indicates that the sale was not a discretionary trade by Madhavan. For deeper insights into insider trading patterns and 12+ additional key metrics for uniQure, visit InvestingPro.
In other recent news, uniQure has made significant strides in its regulatory interactions with the U.S. Food and Drug Administration (FDA) regarding its gene therapy candidate, AMT-130, for Huntington’s disease. The FDA has reaffirmed its support for an accelerated approval path, with a Biologics License Application (BLA) submission anticipated in the first quarter of 2026. This comes as uniQure plans to release three-year top-line data from AMT-130’s ongoing Phase 1/2 study in the third quarter of 2025. Additionally, the company has appointed Kylie O’Keefe as Chief Customer and Strategy Officer, where she will spearhead the commercialization strategy for AMT-130.
In corporate governance developments, uniQure shareholders recently approved executive compensation and board reappointments during the 2025 Annual General Meeting. Key decisions included the re-election of Matthew Kapusta as an executive director and the adoption of the 2024 Dutch statutory annual accounts. Analyst firms, including Stifel and H.C. Wainwright, have reiterated their Buy ratings on uniQure stock, citing confidence in the company’s regulatory progress and the potential impact of AMT-130 as a key value driver. Stifel analysts also highlighted a recent meeting with uniQure leadership, expressing optimism about upcoming data and regulatory submissions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.